Cargando…
Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
Aims In 2021, vericiguat was approved by the US Food and Drug Administration (FDA) and the European Commission (EC) for reducing cardiovascular mortality and heart failure (HF) hospitalizations in patients with HF with reduced ejection fraction (HFrEF) based on the Vericiguat Global Study in Subject...
Autores principales: | Oh, Jaewon, Lee, Chan Joo, Park, Jin Joo, Lee, Sang Eun, Kim, Min‐Seok, Cho, Hyun‐Jai, Choi, Jin‐Oh, Lee, Hae‐Young, Hwang, Kyung‐Kuk, Kim, Kye Hun, Yoo, Byung‐Su, Choi, Dong‐Ju, Baek, Sang Hong, Jeon, Eun‐Seok, Kim, Jae‐Joong, Cho, Myeong‐Chan, Chae, Shung Chull, Oh, Byung‐Hee, Kang, Seok‐Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934970/ https://www.ncbi.nlm.nih.gov/pubmed/35142095 http://dx.doi.org/10.1002/ehf2.13837 |
Ejemplares similares
-
Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry
por: Oh, Jaewon, et al.
Publicado: (2019) -
Heart failure and atrial fibrillation: tachycardia‐mediated acute decompensation
por: Park, Jin Joo, et al.
Publicado: (2021) -
Nutritional risk index as a predictor of mortality in acutely decompensated heart failure
por: Cho, Jae Yeong, et al.
Publicado: (2018) -
In-hospital glycemic variability and all-cause mortality among patients hospitalized for acute heart failure
por: Chun, Kyeong-Hyeon, et al.
Publicado: (2022) -
Prognostic Impact and Predictors of New-Onset Atrial Fibrillation in Heart Failure
por: Choi, Hyo-In, et al.
Publicado: (2022)